Nuvation Bio Q1 net loss $21.3M; pipeline focus on NUV-422, NUV-868, DDC

Nuvation Bio Inc.

2023-Q1 EPS reported -$0.10

Net loss $21.3M ($0.10 per share) vs $20.4M ($0.12) in Q1 2021.
Cash, cash equivalents and marketable securities $737.7M as of March 31, 2022.
R&D expenses $20.7M (up $4.8M YoY); G&A $7.5M (up $2.9M YoY).
On track to initiate Phase 1b combos and Phase 2 monotherapy for NUV-422 by end-2022; first patient dosed in NUV-868 Phase 1.
Deprioritized early-stage NUV-569 and A2A programs to allocate resources to NUV-422, NUV-868, and DDC program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.